DEA Just Ruled on Drug-Test Calibrators: What Telehealth Providers Need to Know
Short version: DEA just worked through a backlog of drug-test calibrator and reference-material applications, and not everything got approved. If your telehealth practice runs urine or oral fluid drug testing as part of patient monitoring, this one’s worth five minutes.
What Did the DEA Just Approve or Deny?
In this May 20, 2026 notice (Docket No. DEA-372, 91 FR 29505), DEA worked through applications submitted between July 1, 2025, and March 31, 2026, for “exempt chemical preparation” status under 21 CFR 1308.23.
Here’s what that status means in plain terms: a lab product containing a trace controlled substance, like a drug-test calibrator or a reference standard, can be exempted from most of the usual CSA handling rules if it’s clearly meant for lab use only and isn’t a meaningful abuse risk. Most applications in this batch got approved. A smaller group got denied.
Why Should Telehealth Providers Care About Lab Calibrators?
Because they’re the backbone of point-of-care drug testing. If you run a buprenorphine or other MAT program, you’re almost certainly using oral fluid or urine test kits to monitor patients. Those kits only stay accurate because of calibrators and controls, exactly what this notice is about.
When a calibrator keeps its exempt status, the company making it doesn’t have to handle it like a full controlled substance, no special registration, no extra recordkeeping. When one loses that status, every step downstream gets stricter, including for whoever’s lab or in-house testing program is using it.
Were Any Drug-Test Calibrators Denied Exemption?
Yes. Lin-Zhi International’s oral fluid MDMA (“Ecstasy”) calibrator and control products, four separate SKUs, were denied. So were several Microgenics control stock solutions covering PCP, methamphetamine, morphine, methadone, and the cocaine metabolite benzoylecgonine.
Worth noting: Microgenics had other products approved in this same notice. Exemption is decided product by product, not company by company, so “we use products from an approved vendor” doesn’t automatically mean every product you use is covered.
What Should Telehealth Providers Do About This?
- Ask your toxicology or point-of-care testing vendor whether anything you use appears in the denied list, especially calibrators tied to MDMA, PCP, methamphetamine, morphine, methadone, or cocaine-metabolite testing.
- If something you rely on lost its exemption, confirm your vendor, or your own lab if you run one in-house, has the DEA registration and recordkeeping to handle it as a controlled substance going forward.
- File a comment under Docket No. DEA-372 before July 20, 2026 if you think a denial was made in error or it affects a product your monitoring program depends on.
- Get in the habit of checking each new “Exempt Chemical Preparations” notice as it’s published. DEA issues these every few months, and your vendor’s product list can shift with each one.
- Consult your compliance counsel.
Source
Federal Register Notice, May 20, 2026: Exempt Chemical Preparations Under the Controlled Substances Act
This post is for educational purposes only and does not constitute legal or compliance advice. Consult a qualified attorney or compliance professional before acting on this information.
